Eptifibatide-induced thrombocytopenia.
Glycoprotein (GP) IIb/IIIa inhibitors reduce major adverse coronary events in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). Unlike the other GPIIb/IIIa inhibitors, eptifibatide is rarely associated with thrombocytopenia with only a few cases reported in the medical literature. Here we report a case of a 34-year-old man presenting with a non ST-elevation myocardial infarction (NSTEMI) who underwent primary PCI with stenting and developed stent thrombosis 5 days after the procedure. He underwent repeat PCI with readministration of eptifibatide and subsequently developed profound thrombocytopenia within 4 h. This report adds another case of eptifibatide associated thrombocytopenia to the literature and reinforces the importance of platelet count monitoring after therapy with this agent.
Refaat
Marwan
M
Cardiovascular Institute, University of Pittsburgh Medical Center, 200 Lothrop Street, Scaife Hall, Suite S553, Pittsburgh, PA 15213, USA. refaatm@upmc.edu
Smith
A J Conrad
AJ
Edmundowicz
Daniel
D
D000328:Adult; D000077542:Eptifibatide; D006801:Humans; D008297:Male; D010455:Peptides / Q000009:adverse effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D010976:Platelet Count; D013921:Thrombocytopenia / Q000139:chemically induced*
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D000077542:Eptifibatide